Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline testing for breast cancer patients in England: illogical to prioritise grade 1 breast cancer aged 30-39 over grade 3 aged 40-49 years?

Journal of medical genetics - 24 Sept 2024

Evans D Gareth, Howell Sacha J, Burghel George J, Forde Claire, Lalloo Fiona, Smith Miriam J, Howell Anthony, Gandhi Ashu, Woodward Emma Roisin

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to England
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Germ-Line Mutation

Share to Neoplasm Grading

Source

Identifiers

PMID: 39054051
DOI: 10.1136/jmg-2024-110183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline testing for breast cancer patients in England: illogical to prioritise grade 1 breast cancer aged 30-39 over grade 3 aged 40-49 years?PMID 39054051Read ↗

Universal genetic testing of patients with newly diagnosed breast cancer - ready for prime time?Semantic proximity Read ↗

Evidence Grows for Universal Germline Genetic Testing for Patients with Breast Cancer.Semantic proximity Read ↗

Update: variable implementation of the 2018 UKCGG/UKGTN guidelines for breast cancer gene panel tests offered by UK genetics services.Semantic proximity Read ↗

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.Semantic proximity Read ↗

Breast cancer multigene germline panel testing in mainstream oncology based on clinical-public health utility (cancer mortality benefit): ESMO Precision Oncology Working Group recommendationsSemantic proximity Read ↗

Genetic testing in women with breast cancer: implications for treatment.Semantic proximity Read ↗

Genetic testing for familial/hereditary breast cancer—comparison of guidelines and recommendations from the UK, France, the Netherlands and GermanySemantic proximity Read ↗

Genetic testing for BRCA1 and BRCA2: recommendations of the Stanford Program in Genomics, Ethics, and Society. Breast Cancer Working Group.Semantic proximity Read ↗

Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelinesSemantic proximity Read ↗

Genetic testing for breast cancer predisposition in 1999: which molecular strategy and which family criteria?Semantic proximity Read ↗

[Germline mutations and breast cancer risk].Semantic proximity Read ↗

Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.